TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04056741

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surfactant airway device
Description: Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
Study: NCT06494410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High versus Low Fraction of Inspired Oxygen
Description: to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High versus Low Fraction of Inspired Oxygen
Description: to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.
Study: NCT05353244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrTMS
Description: Each participant will receive a personalized rTMS treatment based on their individual alpha frequency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Using a sham coil that looks and sounds like an actual TMS coil, each participant will receive sham rTMS treatments.
Study: NCT05967988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive atmospheric projection
Description: Projection of computer-generated videos or videos of real moving landscapes on the walls of the examination room

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Minimal atmospheric projection
Description: Projection of a colors on the walls on the walls of the examination room
Study: NCT05741853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Implemented Script Training for Aphasia (VISTA)
Description: Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Implemented Script Training for Aphasia (VISTA)
Description: Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexical Retrieval Training (LRT)
Description: Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexical Retrieval Training (LRT)
Description: Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
Study: NCT06137573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TNP-2198
Description: 600mg suspension containing 150μCi of \[14C\] TNP-2198
Study: NCT05774665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).
Study: NCT05243485

Intervention type: DIAGNOSTIC_TEST
Intervention: PreHEART
Description: The PreHEART score is validated for use in the pre-hospital setting.The score can be calculated based on five different elements: history, ECG, age, gender, and a Point-of-Care (POC)-Troponin. A minimum of 0 points and a maximum of 2 points can be scored in each element, the total PreHEART can contain a maximum of 10 points. The score of the history is based on the symptoms of the patient in accordance with the symptoms of a myocardial infarction. Based on the suspicion of ischemia on the ECG. Age will be based on the date of birth. Compared to the female gender, the male gender has higher risk of developing myocardial infarction and will be scored higher. The biomarker Troponin will be collected via intravenous access and measured using a POC-analyzer I-Stat from Abbott industries. In total 17 µl of blood is required to fill a cardiac Troponin I (cTnI) cartridge. Analyzing the blood will take approximately 10 minutes.
Study: NCT06625489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3915393
Description: GSK3915393 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3915393
Description: GSK3915393 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3915393
Description: GSK3915393 will be administered.
Study: NCT06618651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-3821 injection
Description: SHR-3821 injection
Study: NCT06625814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: single oral dose
Study: NCT06625242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib Maleate
Description: Administered as oral tablets.
Study: NCT06626256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional Biopsy
Description: Undergo excisional biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Receive standard of care therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Tumor Infiltrating Lymphocytes
Description: Given STIL101 for injection IV
Study: NCT06692673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of Linaclotide as a single agent Colonoscopy prep
Description: We plan to conduct a pilot study to determine the feasibility of a quality bowel preparation with two 290mg doses of Linaclotide (first dose given 36 hours before, and the other 8 hours prior to the procedure) along with 2 Liters of Gatorade (to prevent dehydration) given the day prior to the colonoscopy instead of the current standard 4 liters of PEG regimen. All study participants will be asked to consume a clear liquid diet for 24hours before the procedure.
Study: NCT05260008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 (bupivacaine) implant, one-time administration into the surgical site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 (bupivacaine) implant, one-time administration into the surgical site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine hydrochloride without epinephrine
Description: bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
Study: NCT06695494

Intervention type: DIAGNOSTIC_TEST
Intervention: Gene panel array
Description: Blood sample collection for gene panel testing

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood sample collection for research purposes
Study: NCT05931393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 80 MG
Description: cabozantinib 80mg daily
Study: NCT04732416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15136
Description: Low dose of HM15136/ High dose of HM15136, SC injection, weekly
Study: NCT05503030

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study: NCT06105164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head.
Study: NCT05275972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: Topical Ripasudil 0.4%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical Placebo
Study: NCT06697496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuitBot Smoking Cessation Chatbot Program
Description: Participate in Quitbot chatbot program

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QuitBot Smoking Cessation Text Messaging Program
Description: Participate in Quitbot texting program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide Measurement
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Ancillary studies
Study: NCT06702332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSD-001
Description: MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching Placebo
Study: NCT06693258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroidectomy by robotic surgery via axillary approach
Description: thyroidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy by standard conventional surgery
Description: thyroidectomy by standard conventional surgery
Study: NCT06702592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual support
Description: Subjects will use a virtual support platform that was built for their needs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient educational material
Description: Participants will have access to patient educational material.
Study: NCT06706622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available saline solution
Study: NCT06708182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAGE LEAF Positive Emotion Skills Course
Description: The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
Study: NCT06714656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Swap
Description: Personalised food swaps and dietary advice on how to incorporate these swaps into their usual diet
Study: NCT06716749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 10 mg morphine in 10 mL normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin
Description: 500 mg Vancomycin in 100 mL of normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 500 mg Vancomycin in 100 mL of normal saline
Study: NCT06704594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline 50 mg daily
Description: The intervention will be in the form of an oral pill, taken daily, from the day of positive ovulation result (participants will be taking urine ovulation tests around the days of expected positive ovulation result), until the day of menses onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive ovulation result (participants will be taking urine ovulation tests around the days of expected positive ovulation result), until the day of menses onset.
Study: NCT06721507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirzepatide
Description: Participants will be educated on dietary and lifestyle changes. Participants will self inject 2.5 mg tirzepatide subcutaneously once weekly and maintain a drug administration diary. Dose escalation will proceed per package directions if instructed by study team at follow up visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will be educated on dietary and lifestyle changes
Study: NCT06729723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAT-001
Description: SAT-001 Treatment Group Participants in this group will use the SAT-001 device for 30 minutes. Before and after using the device, choroidal thickness will be measured using Optical Coherence Tomography (OCT) to assess changes in choroidal thickness.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified SAT-001
Description: mSAT-001 Treatment Group Participants in this group will use the modified SAT-001 (mSAT-001) device for 15 minutes. Similar to the SAT-001 group, choroidal thickness will be measured using Optical Coherence Tomography (OCT) before and after device usage.~This protocol will help evaluate the effect of the SAT-001 and modified device on choroidal thickness, with measurements taken before and after each usage.
Study: NCT06706258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days
Description: Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
Description: Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.
Study: NCT06728488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENG Block
Description: The patients in the PENG block group will provide their consent. Standard monitoring will be applied. The patients will be positioned supine. After antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The linear ultrasound probe will be placed in the transverse plane over the AIIS. The position of the ultrasound probe will be verified by visualizing the iliopectineal eminence, iliopsoas muscle and tendon, femoral artery, and pectineus muscle. Using a Stimuplex® A 100 mm 20 gauge needle (Braun Melsungen AG, Melsungen, Germany) with the in-plane technique, the needle will be inserted laterally to medially into the space between the psoas tendon and the pubic ramus. Negative aspiration will be performed to ensure no blood is aspirated, and then 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be injected to perform the PENG block. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENG block and pulse radiofrequency ablation
Description: After obtaining consent, the patients in the PENG block and pulse radiofrequency ablation group will be brought into the operating room. Standard monitoring will be applied (ECG, SpO2, NIBP). The patients will be positioned supine. After performing the necessary aseptic and antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The Boston Scientific unified echogenic 10cmx10mmx20G (0.9mm) radiofrequency cannula will be advanced until it makes contact with the superior ramus near the iliopectineal eminence. Pulse radiofrequency ablation will be performed with two cycles of 90 seconds each, and after each cycle, the needle will be moved 2 mm medially. After pulse radiofrequency ablation, 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be applied. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
Study: NCT06738108

Intervention type: DRUG
Intervention: ECOS
Description: The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE

Intervention type: DRUG
Intervention: Control group
Description: Alteplase IV infusion
Study: NCT05501496

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intramedullary nailing
Description: Flexible intramedullary nailing using 2 nails